Health equity considerations for developing and reporting patient-reported outcomes in clinical trials: A report from the omeract equity special interest group

Jennifer Petkovic, Jennifer Barton, Caroline Flurey, Niti Goel, Christie M. Bartels, Cheryl Barnabe, Maarten P.T. De Wit, Anne Lyddiatt, Diane Lacaille, Vivian Welch, Annelies Boonen, Beverley Shea, Robin Christensen, Lara J. Maxwell, Willemina Campbell, Janet Jull, Karine Toupin-April, Jasvinder A. Singh, Charles H. Goldsmith, Antoine G. SreihChristoph Pohl, Catherine Hofstetter, Dorcas E. Beaton, Rachelle Buchbinder, Francis Guillemin, Peter S. Tugwell

Research output: Contribution to journalReview article

Abstract

Objective: Despite advances integrating patient-centered outcomes into rheumatologic studies, concerns remain regarding their representativeness across diverse patient groups and how this affects equity. The Outcome Measures in Rheumatology (OMERACT) Equity Working Group aims to determine whether and how to address equity issues within the core outcome sets of domains and instruments. Methods: We surveyed current and previous OMERACT meeting attendees and members of the Campbell and Cochrane Equity Group regarding whether to address equity issues within the OMERACT Filter 2.0 Core Outcome Sets and how to assess the appropriateness of domains, instruments, and measurement properties among diverse patients. At OMERACT 2016, results of the survey and a narrative review of differential psychosocial effects of rheumatoid arthritis (i.e., on men) were presented to stimulate discussion and develop a research agenda. Results: We proposed 6 moments for which an equity lens could be added to the development, selection, or testing of patient-reported outcome measures (PROM): (1) recruitment, (2) domain selection, (3) feasibility in diverse settings, (4) instrument validity, (5) thresholds of meaning, and (6) consideration of statistical power of subgroup analyses for outcome reporting. Conclusion: There is a need to (1) conduct a systematic review to assess how equity and population characteristics have been considered in PROM development and whether these differences influence the ranking of importance of outcome domains or a patient's response to questionnaire items, and (2) conduct the same survey described above with patients representing groups experiencing health inequities. The Journal of Rheumatology

Original languageEnglish (US)
Pages (from-to)1727-1733
Number of pages7
JournalJournal of Rheumatology
Volume44
Issue number11
DOIs
StatePublished - Nov 1 2017
Externally publishedYes

Fingerprint

Public Opinion
Clinical Trials
Rheumatology
Population Characteristics
Lenses
Rheumatoid Arthritis
Outcome Assessment (Health Care)
Health Equity
Patient Reported Outcome Measures
Health
Research
Surveys and Questionnaires

Keywords

  • Arthritis
  • Health equity
  • Omeract
  • Rheumatology outcome assessment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Health equity considerations for developing and reporting patient-reported outcomes in clinical trials : A report from the omeract equity special interest group. / Petkovic, Jennifer; Barton, Jennifer; Flurey, Caroline; Goel, Niti; Bartels, Christie M.; Barnabe, Cheryl; De Wit, Maarten P.T.; Lyddiatt, Anne; Lacaille, Diane; Welch, Vivian; Boonen, Annelies; Shea, Beverley; Christensen, Robin; Maxwell, Lara J.; Campbell, Willemina; Jull, Janet; Toupin-April, Karine; Singh, Jasvinder A.; Goldsmith, Charles H.; Sreih, Antoine G.; Pohl, Christoph; Hofstetter, Catherine; Beaton, Dorcas E.; Buchbinder, Rachelle; Guillemin, Francis; Tugwell, Peter S.

In: Journal of Rheumatology, Vol. 44, No. 11, 01.11.2017, p. 1727-1733.

Research output: Contribution to journalReview article

Petkovic, J, Barton, J, Flurey, C, Goel, N, Bartels, CM, Barnabe, C, De Wit, MPT, Lyddiatt, A, Lacaille, D, Welch, V, Boonen, A, Shea, B, Christensen, R, Maxwell, LJ, Campbell, W, Jull, J, Toupin-April, K, Singh, JA, Goldsmith, CH, Sreih, AG, Pohl, C, Hofstetter, C, Beaton, DE, Buchbinder, R, Guillemin, F & Tugwell, PS 2017, 'Health equity considerations for developing and reporting patient-reported outcomes in clinical trials: A report from the omeract equity special interest group', Journal of Rheumatology, vol. 44, no. 11, pp. 1727-1733. https://doi.org/10.3899/jrheum.160975
Petkovic, Jennifer ; Barton, Jennifer ; Flurey, Caroline ; Goel, Niti ; Bartels, Christie M. ; Barnabe, Cheryl ; De Wit, Maarten P.T. ; Lyddiatt, Anne ; Lacaille, Diane ; Welch, Vivian ; Boonen, Annelies ; Shea, Beverley ; Christensen, Robin ; Maxwell, Lara J. ; Campbell, Willemina ; Jull, Janet ; Toupin-April, Karine ; Singh, Jasvinder A. ; Goldsmith, Charles H. ; Sreih, Antoine G. ; Pohl, Christoph ; Hofstetter, Catherine ; Beaton, Dorcas E. ; Buchbinder, Rachelle ; Guillemin, Francis ; Tugwell, Peter S. / Health equity considerations for developing and reporting patient-reported outcomes in clinical trials : A report from the omeract equity special interest group. In: Journal of Rheumatology. 2017 ; Vol. 44, No. 11. pp. 1727-1733.
@article{ff91f4cdef8b4ca48bc93a27c2955c3a,
title = "Health equity considerations for developing and reporting patient-reported outcomes in clinical trials: A report from the omeract equity special interest group",
abstract = "Objective: Despite advances integrating patient-centered outcomes into rheumatologic studies, concerns remain regarding their representativeness across diverse patient groups and how this affects equity. The Outcome Measures in Rheumatology (OMERACT) Equity Working Group aims to determine whether and how to address equity issues within the core outcome sets of domains and instruments. Methods: We surveyed current and previous OMERACT meeting attendees and members of the Campbell and Cochrane Equity Group regarding whether to address equity issues within the OMERACT Filter 2.0 Core Outcome Sets and how to assess the appropriateness of domains, instruments, and measurement properties among diverse patients. At OMERACT 2016, results of the survey and a narrative review of differential psychosocial effects of rheumatoid arthritis (i.e., on men) were presented to stimulate discussion and develop a research agenda. Results: We proposed 6 moments for which an equity lens could be added to the development, selection, or testing of patient-reported outcome measures (PROM): (1) recruitment, (2) domain selection, (3) feasibility in diverse settings, (4) instrument validity, (5) thresholds of meaning, and (6) consideration of statistical power of subgroup analyses for outcome reporting. Conclusion: There is a need to (1) conduct a systematic review to assess how equity and population characteristics have been considered in PROM development and whether these differences influence the ranking of importance of outcome domains or a patient's response to questionnaire items, and (2) conduct the same survey described above with patients representing groups experiencing health inequities. The Journal of Rheumatology",
keywords = "Arthritis, Health equity, Omeract, Rheumatology outcome assessment",
author = "Jennifer Petkovic and Jennifer Barton and Caroline Flurey and Niti Goel and Bartels, {Christie M.} and Cheryl Barnabe and {De Wit}, {Maarten P.T.} and Anne Lyddiatt and Diane Lacaille and Vivian Welch and Annelies Boonen and Beverley Shea and Robin Christensen and Maxwell, {Lara J.} and Willemina Campbell and Janet Jull and Karine Toupin-April and Singh, {Jasvinder A.} and Goldsmith, {Charles H.} and Sreih, {Antoine G.} and Christoph Pohl and Catherine Hofstetter and Beaton, {Dorcas E.} and Rachelle Buchbinder and Francis Guillemin and Tugwell, {Peter S.}",
year = "2017",
month = "11",
day = "1",
doi = "10.3899/jrheum.160975",
language = "English (US)",
volume = "44",
pages = "1727--1733",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "11",

}

TY - JOUR

T1 - Health equity considerations for developing and reporting patient-reported outcomes in clinical trials

T2 - A report from the omeract equity special interest group

AU - Petkovic, Jennifer

AU - Barton, Jennifer

AU - Flurey, Caroline

AU - Goel, Niti

AU - Bartels, Christie M.

AU - Barnabe, Cheryl

AU - De Wit, Maarten P.T.

AU - Lyddiatt, Anne

AU - Lacaille, Diane

AU - Welch, Vivian

AU - Boonen, Annelies

AU - Shea, Beverley

AU - Christensen, Robin

AU - Maxwell, Lara J.

AU - Campbell, Willemina

AU - Jull, Janet

AU - Toupin-April, Karine

AU - Singh, Jasvinder A.

AU - Goldsmith, Charles H.

AU - Sreih, Antoine G.

AU - Pohl, Christoph

AU - Hofstetter, Catherine

AU - Beaton, Dorcas E.

AU - Buchbinder, Rachelle

AU - Guillemin, Francis

AU - Tugwell, Peter S.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Objective: Despite advances integrating patient-centered outcomes into rheumatologic studies, concerns remain regarding their representativeness across diverse patient groups and how this affects equity. The Outcome Measures in Rheumatology (OMERACT) Equity Working Group aims to determine whether and how to address equity issues within the core outcome sets of domains and instruments. Methods: We surveyed current and previous OMERACT meeting attendees and members of the Campbell and Cochrane Equity Group regarding whether to address equity issues within the OMERACT Filter 2.0 Core Outcome Sets and how to assess the appropriateness of domains, instruments, and measurement properties among diverse patients. At OMERACT 2016, results of the survey and a narrative review of differential psychosocial effects of rheumatoid arthritis (i.e., on men) were presented to stimulate discussion and develop a research agenda. Results: We proposed 6 moments for which an equity lens could be added to the development, selection, or testing of patient-reported outcome measures (PROM): (1) recruitment, (2) domain selection, (3) feasibility in diverse settings, (4) instrument validity, (5) thresholds of meaning, and (6) consideration of statistical power of subgroup analyses for outcome reporting. Conclusion: There is a need to (1) conduct a systematic review to assess how equity and population characteristics have been considered in PROM development and whether these differences influence the ranking of importance of outcome domains or a patient's response to questionnaire items, and (2) conduct the same survey described above with patients representing groups experiencing health inequities. The Journal of Rheumatology

AB - Objective: Despite advances integrating patient-centered outcomes into rheumatologic studies, concerns remain regarding their representativeness across diverse patient groups and how this affects equity. The Outcome Measures in Rheumatology (OMERACT) Equity Working Group aims to determine whether and how to address equity issues within the core outcome sets of domains and instruments. Methods: We surveyed current and previous OMERACT meeting attendees and members of the Campbell and Cochrane Equity Group regarding whether to address equity issues within the OMERACT Filter 2.0 Core Outcome Sets and how to assess the appropriateness of domains, instruments, and measurement properties among diverse patients. At OMERACT 2016, results of the survey and a narrative review of differential psychosocial effects of rheumatoid arthritis (i.e., on men) were presented to stimulate discussion and develop a research agenda. Results: We proposed 6 moments for which an equity lens could be added to the development, selection, or testing of patient-reported outcome measures (PROM): (1) recruitment, (2) domain selection, (3) feasibility in diverse settings, (4) instrument validity, (5) thresholds of meaning, and (6) consideration of statistical power of subgroup analyses for outcome reporting. Conclusion: There is a need to (1) conduct a systematic review to assess how equity and population characteristics have been considered in PROM development and whether these differences influence the ranking of importance of outcome domains or a patient's response to questionnaire items, and (2) conduct the same survey described above with patients representing groups experiencing health inequities. The Journal of Rheumatology

KW - Arthritis

KW - Health equity

KW - Omeract

KW - Rheumatology outcome assessment

UR - http://www.scopus.com/inward/record.url?scp=85032624878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032624878&partnerID=8YFLogxK

U2 - 10.3899/jrheum.160975

DO - 10.3899/jrheum.160975

M3 - Review article

C2 - 28202740

AN - SCOPUS:85032624878

VL - 44

SP - 1727

EP - 1733

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 11

ER -